Analysis of Risks and Returns in Selling SRPT Options
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3h ago
0mins
Source: NASDAQ.COM
- Options Selling Risk: Selling puts on SRPT does not provide the same upside potential as owning shares, as the put seller only acquires shares if the contract is exercised, otherwise they only collect the premium.
- Market Price Impact: If Sarepta Therapeutics' shares do not decline by 26.4%, the put seller can only achieve a 22.2% annualized return, highlighting the asymmetric risk-reward profile of this options selling strategy.
- Volatility Analysis: With a trailing twelve-month volatility of 119% calculated from the last 251 trading days, this metric serves as a crucial reference for investors assessing the risk-reward of selling the January 2027 put at the $15 strike price.
- Market Strategy Recommendation: Investors should carefully evaluate whether selling SRPT puts under current market conditions is worthwhile, ensuring a reasonable alignment between risk and potential returns based on historical volatility and fundamental analysis.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRPT
Wall Street analysts forecast SRPT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRPT is 20.80 USD with a low forecast of 5.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
4 Buy
10 Hold
4 Sell
Hold
Current: 21.235
Low
5.00
Averages
20.80
High
45.00
Current: 21.235
Low
5.00
Averages
20.80
High
45.00
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of Risks and Returns in Selling SRPT Options
- Options Selling Risk: Selling puts on SRPT does not provide the same upside potential as owning shares, as the put seller only acquires shares if the contract is exercised, otherwise they only collect the premium.
- Market Price Impact: If Sarepta Therapeutics' shares do not decline by 26.4%, the put seller can only achieve a 22.2% annualized return, highlighting the asymmetric risk-reward profile of this options selling strategy.
- Volatility Analysis: With a trailing twelve-month volatility of 119% calculated from the last 251 trading days, this metric serves as a crucial reference for investors assessing the risk-reward of selling the January 2027 put at the $15 strike price.
- Market Strategy Recommendation: Investors should carefully evaluate whether selling SRPT puts under current market conditions is worthwhile, ensuring a reasonable alignment between risk and potential returns based on historical volatility and fundamental analysis.
Continue Reading
U.S. Natural Gas Prices Surge Over 30% Amid Winter Storm
- Natural Gas Surge: U.S. natural gas prices soared over 30% on Monday due to Winter Storm Fern disrupting supply and sharply increasing heating demand, with the Henry Hub front-month contract now trading above $6 per million British thermal units, marking a 125% increase from just a week ago.
- Precious Metals Rally: The weakening dollar fueled a broader commodity breakout, with gold rising 2.2% to $5,100 and silver surging 13% to $116 per ounce, achieving its best one-day gain since September 2008 and lifting its rolling 12-month gain to 266%, the strongest since 1980.
- Tech Stocks Outperform: Amid ongoing supply disruptions in the DRAM market, memory-linked stocks such as Seagate, Western Digital, and SanDisk extended their gains, contributing to a stronger performance in technology stocks as the S&P 500 sits less than half a percentage point from record highs.
- Major Indices Performance: The Nasdaq 100 rose 0.7% to 25,796.15, the S&P 500 increased 0.7% to 6,966.04, and the Dow Jones Industrial Average climbed 0.5% to 49,350.28, reflecting overall market optimism.
Continue Reading